Literature DB >> 6449432

[Trans-catheter embolisation of the spleen with butyl-2-cyanoacrylate. Experimental results and clinical application (author's transl)].

R Günther, J Bohl, K Klose, J Anger.   

Abstract

Partial and total trans-catheter embolisation of the spleen with butyl-2-cyanoacrylate-lipiodol in 23 dogs lead to partial necrosis and cicatrisation of the spleen after 3 to 5 weeks. The embolised vessels do not recanalise, but are by-passed by extra- and intra-splenic collaterals. In five animals there was a reduction in the number of erythrocytes; after embolisation there was increase in the number of leucocytes, whereas the thrombocytes were unchanged. The most common complication which occurred in five animals was a 1.5 to 2.5 cm. splenic abscess. The procedure was employed without success in one patient with bleeding oesophageal varices. The procedure was complicated by extensive necrosis of the gastric mucosa. Trans-catheter embolisation of the spleen has significant complications, despite strict asepsis and antibiotic cover. The main indication of the procedure is hypersplenism which cannot be treated surgically.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6449432     DOI: 10.1055/s-2008-1056697

Source DB:  PubMed          Journal:  Rofo        ISSN: 1438-9010


  3 in total

1.  [Radiologic alternatives of splenectomy].

Authors:  R Schuster
Journal:  Langenbecks Arch Chir       Date:  1986

2.  Evaluation of splenic embolization in patients with portal hypertension and hypersplenism.

Authors:  A Alwmark; S Bengmark; P Gullstrand; B Joelsson; A Lunderquist; T Owman
Journal:  Ann Surg       Date:  1982-11       Impact factor: 12.969

3.  Partial splenic embolisation using n-butyl cyanoacrylate: intraprocedural evaluation by magnetic resonance imaging.

Authors:  Jun Koizumi; Chihiro Itou; Rick Wray; Kazunori Myojin; Takeshi Hashimoto; Yoshimi Nagata; Hiroshi Yamamuro; Tomoatsu Tsuji; Tamaki Ichikawa; Kouichi Shiraishi; Tatehiro Kagawa; Tetsuya Mine; Norihito Watanabe; Mitsunori Matsumae; Bertrand Janne d'Othée
Journal:  Eur Radiol       Date:  2012-11-19       Impact factor: 5.315

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.